3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Three small-cap biotechs, Kodiak Sciences, Capricor Therapeutics, and Invivyd, face binary clinical trial or FDA decisions before the end of 2026.

Kodiak's Phase 3 DAYBREAK results for wet AMD, due between September and December 2026, could ease balance sheet concerns after widening losses.

Capricor awaits a delayed Nov. 22, 2026, FDA decision on Deramiocel, while Invivyd anticipates Phase 3 DECLARATION results for its COVID-19 antibody VYD2311.

For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.

When that moment arrives, there's rarely a middle ground: a positive result can send shares sharply higher and validate years of spending, while a miss can wipe out most of the market cap overnight. That's what makes these "binary catalysts" so important to track, and so risky to hold through.

Below are three small-cap biotechs facing exactly that kind of moment before the end of 2026. Each has a different disease, a different drug, and a different timeline, but all three share the same setup: one event, largely beyond the company's control, that could reset the stock's trajectory with a single announcement.

Kodiak Sciences: A Wet AMD Verdict That Could Reset the Balance Sheet

Kodiak Sciences (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for retinal diseases. What's driving interest in KOD in late 2026 is the expected results from the company's Phase 3 DAYBREAK study.

DAYBREAK is testing two of Kodiak's drug candidates, Zenkuda and KSI-501, in patients who have never been treated for wet age-related macular degeneration (wet AMD). Wet AMD is a leading cause of vision loss in which abnormal blood vessels leak fluid behind the retina.

Because each drug is being evaluated separately against aflibercept, the current standard of care, DAYBREAK is effectively two readouts packaged into one headline event. Both comparisons test whether Kodiak's candidate can match aflibercept's vision and safety outcomes while requiring fewer eye injections over the course of a year, with roughly 690 patients enrolled across the two.